Oxytocin stimulates migration and invasion in human endothelial cells

British Journal of Pharmacology

Volumn 153, Issue 4, 2008, Pages 728-736

  Cattaneo, M G ^a   Chini, B ^b   Vicentini, L M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

Author keywords

Angiogenesis; Human endothelial cells; Invasion; Motility; Nitric oxide; Oxytocin; Phosphatidylinositol 3 kinase AKT pathway; Phospholipase C

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYTOCIN; OXYTOCIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PHOSPHOLIPASE C INHIBITOR; PROTEIN KINASE B; SEMAXANIB;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CHEMOTAXIS; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; UMBILICAL VEIN;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELLS, CULTURED; CHEMOTAXIS; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENDOTHELIAL CELLS; ENZYME INDUCTION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HUMANS; LAMININ; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXYTOCIN; PHOSPHORYLATION; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, OXYTOCIN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TYPE C PHOSPHOLIPASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 39449121993     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707609     Document Type: Article

References (36)

1. Albini A, Benelli R, Noonan DM, Brigati C (2004). The 'chemoinvasion assay': a tool to study tumor and endothelial cell invasion of basement membranes. Int J Dev Biol 48: 563-571.
2. Bergers G, Benjamin LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
3. Bussolati G, Cassoni P (2001). The oxytocin/oxytocin receptor system: expect the unexpected. Endocrinology 142: 1130-1136.
4. Cassoni P, Marrocco T, Bussolati B, Allia E, Munaron I, Sapino A et al. (2006). Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. Mol Cancer Res 4: 351-359.
5. Cassoni P, Sapino A, Deaglio S, Bussolati B, Volante M, Munaron L et al. (2002). Oxytocin is a growth factor for Kaposi's sarcoma cells: evidence of endocrine-immunological cross-talk. Cancer Res 62: 2406-2413.
6. Cassoni P, Sapino A, Marrocco T, Chini B, Bussolati G (2004). Oxytocin and oxytocin receptors in cancer cells and proliferation. J Neuroendocrinol 16: 362-364.
7. Cattaneo MG, Pola S, Francescato P, Chillemi F, Vicentini LM (2003). Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp Cell Res 283: 230-236.
8. Chini B, Manning M (2007). Agonist selectivity in the oxytocin/ vasopressin receptor family: new insights and challanges. Biochem Soc Trans 35: 737-741.
9. Dimmeler S, Dernbach E, Zeiher AM (2000). Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 477: 258-262.
10. Dudzinski DM, Igarashi J, Greif D, Michel T (2006). The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 46: 235-276.
11. Elands J, Barberis C, Jard S, Tribollet E, Dreifuss JJ, Bankowski K et al. (1988). I-Labelled d(CH2)5[Tyr(Me)2, Thr4, Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand. Eur J Pharmacol 147: 197-207.
12. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO et al. (2001). Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 98: 2604-2609.
13. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48: 184-188.
14. Gimpl G, Fahrenholz F (2001). The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81: 629-683.
15. Guzzi F, Zanchetta D, Cassoni P, Guzzi V, Francolini M, Parenti M et al. (2002). Localisation of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response. Oncogene 21: 1658-1667.
16. Jaffe EA, Nachman RL, Becker CG, Minick CR (1973). Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52: 2745-2756.
17. Leyendecker G, Kunz G, Noe M, Herbertz M, Mall G (1998). Endometriosis: a dysfunction and disease of the archimetra. Hum Reprod Update 4: 752-762.
18. Moolenaar WH (1999). Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 253: 230-238.
19. Moolenaar WH, van Meeteren LA, Giepmans BN (2004). The ins and outs of lysophosphatidic acid signaling. Bioessays 26: 870-881.
20. Morbidelli L, Donnini S, Ziche M (2003). Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Des 9: 521-530.
21. Morita T, Shibata K, Kikkawa F, Kajiyama H, Ino K, Mizutani S (2004). Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo. Int J Cancer 109: 525-532.
22. Murphy PM (1994). The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 12: 593-633.
23. Phaneuf S, Carrasco MP, Europe-Finner GN, Hamilton CH, Lopez Bernal A (1996). Multiple G proteins and phospholipase C isoforms in human myometrial cells: implication for oxytocin action. J Clin Endocrinol Metab 81: 2098-2103.
24. Reversi A, Rimoldi V, Marrocco T, Cassoni P, Bussolati G, Parenti M et al. (2005). The oxytocin receptor antagonist atosiban inhibits cell growth via a 'biased agonist' mechanism. J Biol Chem 280: 16311-16318.
25. Reynolds LP, Grazul-Bilska AT, Redmer DA (2002). Angiogenesis in the female reproductive organs: pathological implications. Int J Exp Pathol 83: 151-163.
26. Rimoldi V, Reversi A, Taverna E, Rosa P, Francolini M, Cassoni P et al. (2003). Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains. Oncogene 22: 6054-6060.
27. Rosen H, Goetzl EJ (2005). Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 5: 560-570.
28. Sanborn BM (2001). Hormones and calcium: mechanisms controlling uterine smooth muscle contractile activity. The Litchfield Lecture. Exp Physiol 86: 223-237.
29. Serradeil-Le Gal C, Wagnon J, Garcia C, Lacour C, Gulraudou P, Christophe B et al. (1993). Biochemical and pharmacological properties of SR49059, a new, potent, non peptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest 92: 224-231.
30. Shibuya M, Claesson-Welsh L (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312: 549-560.
31. Steinwall M, Hansson S, Bossmar T, Larsson I, Pilka R, Akerlund M (2004). Oxytocin mRNA content in the endometrium of non-pregnant women. BJOG 111: 266-270.
32. i receptor interaction. Am J Physiol 272: E870-E876.
33. Thelen M (2001). Dancing to the tune of chemokines. Nat Immunol 2: 129-134.
34. Thibonnier M, Conarty DM, Preston JA, Plesnicher CL, Dweik RA, Erzurum SC (1999). Human vascular endothelial cells express oxytocin receptors. Endocrinology 140: 1301-1309.
35. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H et al. (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
36. Van Haastert PJ, Devreotes PN (2004). Chemotaxis: signalling the way forward. Nat Rev Mol Cell Biol 5: 626-634.